$0.59
+0.01 (+1.35%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RDHL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 1 expanded access · 10 with posted results
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 YearsNCT04026984Clinical CureRandomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: Rifamycin SV-MMX, Placebo | Traveler's Diarrhea | 142 | Jun 2025 | 2023-01-27 |
| Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 YearsNCT04027894Clinical CureRandomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: Rifamycin SV MMX, Placebo to Rifamycin SV-MMX | Traveler's Diarrhea | 142 | Jan 2025 | 2023-01-27 |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: extremely slow enrollment into study | Drug: RHB-204, Placebo | Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases | 12 | 2023-08-28actual | 2025-03-18 |
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaNCT03377179Part1 - Determine Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: ABC294640, Hydroxychloroquine Sulfate 200 MG | Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic | 65 | 2022-06-21actual | 2025-07-23 |
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537results2024-06-06Part A - Determination of the Safety and Tolerability of Two Dose Levels and Selection of an Upamostat Dose for Part BRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Part A complete; corporate decision made to cancel Part B. | Drug: Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg | Covid19 | 61 | 2021-12-28actual | 2024-06-06 |
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840results2023-10-19Supplemental Oxygen RequirementRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Opaganib, Placebo | COVID-19, Lung Infection | 475 | 2021-07-18actual | 2025-07-31 |
| Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring OxygenNCT04502069Time to breathing room airOpen-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: To be replaced with a randomized placebo-controlled study. | Drug: Opaganib | COVID-19, Lung Infection | 0 | Feb 2021 | 2020-08-11 |
| A Study of Opaganib in Coronavirus Disease 2019 PneumoniaNCT04414618results2022-03-21Measurement of the Change in Oxygen Requirement From BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Opaganib, Placebo | Coronavirus Infections | 42 | 2020-11-26actual | 2022-03-21 |
| Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaNCT02229981Determine Maximum tolerated dose (MTD) of ABC294640 in patients with refractory/relapsed DLBCL or KS and determine tolerability at MTD.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Study was discontinued due to lack of recruitment. | Drug: ABC294640 | Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | 0 | Jun 2019 | 2017-12-07 |
| ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaNCT02757326results2021-06-18Maximum Tolerated DoseOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Expiration of National Cancer Institute (NCI) funding of the study. | Drug: Opaganib | Multiple Myeloma | 13 | May 2019actual | 2021-06-18 |
| Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's DiseaseNCT03009396results2021-02-24Number of Patients in Remission at Week 16Non-randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) | Crohn Disease | 54 | 2018-11-13actual | 2021-02-24 |
| ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active ComparatorNCT03198507results2020-03-16Number of Participants With Eradication of H. PyloriRandomized · Triple-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: RHB-105, Active Comparator | Helicobacter Pylori Infection, Dyspepsia | 455 | 2018-10-24actual | 2020-03-16 |
| Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's DiseaseNCT01951326results2020-05-01Remission at Week 26Randomized · Double-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: RHB-104, Placebo | Crohn's Disease | 331 | May 2018actual | 2020-12-08 |
| Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)NCT02757105results2018-07-31Summary and Analysis of Overall Stool Consistency Response Rate - mITT PopulationRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BEKINDA, Placebo | Irritable Bowel Syndrome With Diarrhea | 127 | 2017-06-16actual | 2018-08-28 |
| BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or GastritisNCT02246439results2019-02-20Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT PopulationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: RHB-102, Placebo Oral Tablet | Gastroenteritis, Gastritis | 330 | 2017-02-13actual | 2019-02-20 |
| Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)NCT01717664Combined Unique Active lesionsOpen-label · Treatment | Phase 2 | Completed | Drug: RHB-104 | Relapsing Remitting Multiple Sclerosis | 18 | Dec 2015actual | 2016-07-28 |
| ERADICATE Hp - Treating Helicobacter Pylori With RHB-105NCT01980095results2017-01-10The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT TestingRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: RHB-105, Placebo | Dyspepsia, Helicobacter Pylori Infection | 119 | Jun 2015actual | 2019-09-24 |
| ABC294640 in Treating Patients With Advanced Solid TumorsNCT01488513Maximum tolerated dose (MTD) defined as highest dose of ABC294640 at which 0 or 1 patient of 6 experiences a DLT.Open-label · Treatment | Phase 1 | Completed | Drug: sphingosine kinase-2 inhibitor ABC294640 | Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 22 | Aug 2014actual | 2020-01-07 |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)NCT03414489expanded access | — | No longer available | Drug: ABC294640 | Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic | — | — | 2025-03-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19